Sugi Predict

Sugi Predict / Compounds / SCHEMBL22354643

SCHEMBL22354643

SCHEMBL22354643

CCCS(=O)(=O)CCN1CCN(CC(=O)O)CCN(CC(=O)O)CC1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.39
▸ S1PR1 P21453 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ APEX1 P27695 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ SLC6A9 P48067 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23904651 0.89 HSD17B10 (0.41) HSD17B10S1PR1CYP1A2APEX1ALOX15
SCHEMBL22779191 0.86 SMN1; SMN2 (0.40) HSD17B10S1PR1KDM4ECYP1A2CYP2D6
SCHEMBL22354582 0.82 HSD17B10 (0.36) HSD17B10S1PR1KDM4EAPEX1SLC6A9
SCHEMBL19016168 0.82 HSD17B10 (0.36) HSD17B10S1PR1APEX1SLC6A9
SCHEMBL26434198 0.82 HSD17B10 (0.36) HSD17B10S1PR1APEX1SLC6A9
SCHEMBL22344786 0.81 HSD17B10 (0.40) HSD17B10S1PR1CYP1A2APEX1SLC6A9
SCHEMBL22344784 0.81 HSD17B10 (0.40) HSD17B10S1PR1CYP1A2APEX1SLC6A9
SCHEMBL15499048 0.79 HSD17B10 (0.48) HSD17B10S1PR1CYP1A2SLC6A9
SCHEMBL15499754 0.79 HSD17B10 (0.48) HSD17B10S1PR1CYP1A2SLC6A9
SCHEMBL10060138 0.79 HSD17B10 (0.48) HSD17B10S1PR1CYP1A2SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2023-04-27 — — US disclosed
WO-2021198229-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES ANTAROS MEDICAL AB (SE) 2021-10-07 — — WO disclosed
US-11046743-B2 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes ANTAROS MEDICAL AB (SE) 2021-06-29 — — US disclosed
US-20200262885-A1 SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES ANTAROS MEDICAL AB (SE) 2020-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127047-A1 SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES GIPR, GRPR, GLP1R HSD17B10 4682/4885S1PR1 460/4885KDM4E 4192/4885
US-20200262885-A1 SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES GLP1R, GCGR, GIPR HSD17B10 4571/4885S1PR1 899/4885KDM4E 2321/4885
US-11046743-B2 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes GLP1R, GCGR, GIPR HSD17B10 4571/4885S1PR1 899/4885KDM4E 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.